Three FDA advisory panel members resign over approval of Alzheimer’s drug
Three members of a US Food and Drug Administration (FDA) advisory committee, which advised against authorising the Alzheimer’s disease drug aducanumab because of a lack of efficacy, have resigned…
Read Original Article: Three FDA advisory panel members resign over approval of Alzheimer’s drug »
